At 25.9% CAGR, the Middle East & Africa Vitamin K2 Market is projected to be worth US$ 16.83 million by 2030, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa vitamin K2 market was valued at US$ 2.67 million in 2022 and is expected to reach US$ 16.83 million by 2030, registering a CAGR of 25.9% from 2022 to 2030. Increasing prevalence of CVD and growing cases of osteoporosis bone deformation in adults and newborns are among the critical factors attributed to the Middle East & Africa vitamin K2 market expansion.

Cardiovascular disease (CVD) continues to be a significant global health concern, with its prevalence steadily increasing in recent years. This rise is due to the aging population, sedentary lifestyles, and poor dietary choices, along with the growing prevalence of risk factors, including diabetes, hypercholesterolemia, and hypertension. According to World Health Organization, CVD is a leading cause of death with ~17.9 million deaths every year globally.

Researchers are exploring various preventive and therapeutic approaches to combat CVD. One area of interest is the potential role of vitamin K2 in cardiovascular health. Vitamin K2, or menaquinone, is a form of vitamin K linked to potential cardiovascular benefits. A critical mechanism by which vitamin K2 impacts cardiovascular health is its role in regulating calcium metabolism. Arterial calcification, the process of calcium deposits accumulating in the arterial walls, contributes to the development of atherosclerosis, a major underlying cause of CVD. Vitamin K2 has been found to play a significant role in inhibiting arterial calcification by activating proteins that help regulate calcium deposition, thus reducing the risk of atherosclerosis and related cardiovascular disorders.

Several observational studies have examined the potential association between vitamin K2 intake and CVD outcomes. While these studies are unable to establish a definitive cause-and-effect relationship, they have provided interesting insights. A study by the Journal of Nutrition found that higher vitamin K2 intake was linked to a lower risk of coronary heart disease mortality. Further, vitamin K2 should be considered a potential adjunctive therapy or preventive measure alongside lifestyle changes. These modifications include adopting a balanced diet rich in fruits, whole grains, vegetables, and lean proteins; maintaining a healthy weight; engaging in regular physical activity; managing blood pressure and cholesterol levels; and stopping smoking habits. Thus, the increasing prevalence of CVD is driving the Middle East & Africa vitamin K2 market.

On the contrary, limited awareness regarding benefits of vitamin K2 hampers the Middle East & Africa vitamin K2 market.

Based on product, the Middle East & Africa vitamin K2 market is segmented into MK-4, MK-7, and combination drugs. The MK-7 segment held 66.1% share of Middle East & Africa vitamin K2 market in 2022, amassing US$ 1.77 million. It is projected to garner US$ 11.31 million by 2030 to expand at 26.1% CAGR during 2022-2030.

Based on dosage forms, the Middle East & Africa vitamin K2 market is segmented into capsules & tablets, powder, and oils. The powder segment held 59.7% share of Middle East & Africa vitamin K2 market in 2022, amassing US$ 1.60 million. It is projected to garner US$ 10.39 million by 2030 to expand at 26.4% CAGR during 2022-2030.

Based on source, the Middle East & Africa vitamin K2 market is segmented into natural and synthetic. The natural segment held 84.9% share of Middle East & Africa vitamin K2 market in 2022, amassing US$ 2.27 million. It is projected to garner US$ 14.42 million by 2030 to expand at 26.0% CAGR during 2022-2030.

Based on application, the Middle East & Africa vitamin K2 market is segmented into pharmaceuticals, nutraceuticals and food, and others. The pharmaceuticals segment held 63.0% share of Middle East & Africa vitamin K2 market in 2022, amassing US$ 1.68 million. It is projected to garner US$ 10.28 million by 2030 to expand at 25.4% CAGR during 2022-2030.

Based on country, the Middle East & Africa vitamin K2 market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 33.0% share of Middle East & Africa vitamin K2 market in 2022. It was assessed at US$ 0.88 million in 2022 and is likely to hit US$ 5.46 million by 2030, exhibiting a CAGR of 25.6% during 2022-2030.

Key players operating in the Middle East & Africa vitamin K2 market are BASF SE, Glanbia Plc, International Flavors & Fragrances Inc, Koninklijke DSM NV, Lesaffre et Cie SA, Lonza Group AG, and Novozymes AS, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com